Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.13 USD | -1.59% |
|
-10.78% | +28.60% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.60% | 2.09B | |
+75.69% | 12.57B | |
+11.60% | 7.21B | |
-30.38% | 6.82B | |
+11.54% | 5.35B | |
-20.60% | 4.59B | |
+10.66% | 3.95B | |
-21.44% | 3.69B | |
-29.13% | 2.64B | |
-1.36% | 2.03B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Transcript : NovoCure Limited Presents at JP Morgan 37th Annual Healthcare conference, Jan-09-2019 02